Radiation recall dermatitis with gatifloxacin: a review of literature.
Radiation recall dermatitis (RRD) is a hypersensitivity skin reaction at the previously irradiated site after the administration of certain pharmacologic agent, which recovers on stopping the medication. RRD is a well-recognized phenomenon with the use of chemotherapeutic agents; however, only a few cases have been reported with noncytotoxic antibiotics, despite their common use in patients with cancer. We report here a case of RRD with the use of gatifloxacin and describe the time dose factors of radiation exposure, characteristics of skin reactions, management and response and our reasons to label this case as RRD. We also discuss published work regarding proposed mechanisms, histological features, radiation dose threshold and response to rechallange with the RRD-triggering drug. If RRD is to be characterized unequivocally, all the potential areas of confusion must be clarified like radiosensitization, nonhealing of acute reactions and skin-related adverse effects of the RRD-triggering drug. With the same objective, we further discussed radiosensitization and photosensitizing potential of fluoroquinolones. Gatifloxacin, although devoid of photosensitivity reactions, may cause idiosyncratic hypersensitivity reaction to cause RRD and should be considered as a potential cause of RRD. Given the potential severity of the reaction and increasing use of gatifloxacin, it is important to be aware of this phenomenon.
Jain
S
S
Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, India. sandeep740@yahoo.com
Agarwal
J
J
Laskar
S
S
Gupta
T
T
Shrivastava
S
S
D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy*; D004307:Dose-Response Relationship, Radiation; D003875:Drug Eruptions / Q000209:etiology; D005260:Female; D024841:Fluoroquinolones / Q000008:administration & dosage / Q000009:adverse effects*; D005500:Follow-Up Studies; D000077734:Gatifloxacin; D006801:Humans; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000532:radiotherapy*; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage / Q000009:adverse effects; D011855:Radiodermatitis / Q000139:chemically induced*; D012141:Respiratory Tract Infections / Q000188:drug therapy; D013997:Time Factors
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D011838:Radiation-Sensitizing Agents; D000077734:Gatifloxacin